Abstract
Despite progress in clinical treatment, cardiovascular diseases are still the leading cause of morbidity and mortality worldwide. Therefore, novel therapeutic approaches are needed, targeting the underlying molecular mechanisms of disease with improved outcomes for patients. Gene therapy is one of the most promising fields for the development of new treatments for the advanced stages of cardiovascular diseases. The establishment of clinically relevant methods of gene transfer remains one of the principal limitations on the effectiveness of gene therapy. Recently, there have been significant advances in direct and transvascular gene delivery methods. The ideal gene transfer method should be explored in clinically relevant large animal models of heart disease to evaluate the roles of specific molecular pathways in disease pathogenesis. Characteristics of the optimal technique for gene delivery include low morbidity, an increased myocardial transcapillary gradient, esxtended vector residence time in the myocytes, and the exclusion of residual vector from the systemic circulation after delivery to minimize collateral expression and immune response. Here we describe myocardial gene transfer techniques with molecular cardiac surgery with recirculating delivery in a large animal model of post ischemic heart failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2014) Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 129:e28–e292
Hedman M, Hartikainen J, Yla-Herttuala S (2011) Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 18:743–749
Katz MG, Fargnoli AS, Williams RD, Bridges CR (2015) Gene and cell therapy for cardiovascular disease. In: Templeton N (ed) Gene and cell therapy: therapeutic mechanisms and strategies, vol 34, 4th edn. Taylor & Francis Group, New York, NY, pp 861–900
Tilemann L, Ishikawa K, Weber T, Hajjar RJ (2012) Gene therapy for heart failure. Circ Res 110:777–793
Hammoudi N, Ishikawa K, Hajjar RJ (2015) Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr Opin Cardiol 30:228–234
Melo LG, Pachori AS, Gnecchi M, Dzau VJ (2005) Genetic therapies for cardiovascular diseases. Trends Mol Med 11:240–250
Ishikawa K, Aguero J, Naim C, Fish K, Hajjar RJ (2013) Percutaneous approaches for efficient cardiac gene delivery. J Cardiovasc Tranl Res 6:649–659
French BA, Mazur W, Geske RS, Bolli R (1994) Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 90:2414–2424
Rosengart TK, Bishawi MM, Halbreiner MS, Fakhoury M, Finnin E, Hollmann C (2013) Long- term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther 24:203–208
Mäkinen PI, Ylä-Herttuala S (2013) Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. Curr Opin Lipidol 24:116–122
Hajjar RJ, del Monte F, Matsui T, Rosenzweig A (2000) Prospects for gene therapy for heart failure. Circ Res 86:616–621
Boekstegers P, Kupatt C (2004) Current concepts and applications of coronary venous retroinfusions. Basic Res Cardiol 99:373–381
Rapti K, Chaanine AH, Hajjar RJ (2011) Targeted gene therapy for the treatment of heart failure. Can J Cardiol 27:265–283
Katz MG, Fargnoli AS, Bridges CR (2013) Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability. Hum Gene Ther 24:375–392
Katz MG, Fargnoli AS, Williams RD, Steuerwald NM, Isidro A, Ivanina AV, Sokolova IM, Bridges CR (2014) Safety and efficacy of high-dose adeno-associated virus 9 encoding SERCA2a delivered by molecular cardia surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg 148:1065–1072
Acknowledgments
The protocol was developed with the grant support from the NIH (1-R01 HL083078-01A2). We acknowledge the NHLBI Gene Therapy Resource Program (GTRP). Also we thank the veterinarians and veterinary technicians at Carolinas Medical Center and University of Pennsylvania.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Katz, M.G., Fargnoli, A.S., Kendle, A.P., Bridges, C.R. (2017). Molecular Cardiac Surgery with Recirculating Delivery (MCARD): Procedure and Vector Transfer. In: Ishikawa, K. (eds) Cardiac Gene Therapy. Methods in Molecular Biology, vol 1521. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6588-5_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6588-5_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6586-1
Online ISBN: 978-1-4939-6588-5
eBook Packages: Springer Protocols